Increasing importance of European lineages in seeding the hepatitis C virus subtype 1a epidemic in Spain by Pérez, Ana Belén et al.
1www.eurosurveillance.org
Research
Increasing importance of European lineages in seeding 
the hepatitis C virus subtype 1a epidemic in Spain
Ana Belen Pérez1,2, Bram Vrancken2,3, Natalia Chueca¹, Antonio Aguilera⁴, Gabriel Reina⁵, Miguel García-del Toro⁶, Francisco 
Vera⁷, Miguel Angel Von Wichman⁸, Juan Ignacio Arenas⁸, Francisco Téllez9, Juan A Pineda10, Mohamed Omar11, Enrique Bernal12, 
Antonio Rivero-Juárez13, Elisa Fernández-Fuertes14, Alberto de la Iglesia15, Juan Manuel Pascasio16, Philippe Lemey³, Féderico 
Garcia1,2, Lize Cuypers2,17
1. Department of Microbiology, Institute of Bio Sanitary Research (IBIS), AIDS Research Network, University Hospital of Granada, 
Granada, Spain
2. These authors contributed equally to the article
3. KU Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Evolutionary and 
Computational Virology, Leuven, Belgium
4. Department of Microbiology, University Hospital of Santiago, Santiago de Compostela, Spain
5. Department of Microbiology, University Hospital of Navarra, Institute for Health Research (IdisNA), Pamplona, Spain
6. Unit of Infectious Diseases, General Hospital of Valencia, Valencia,
7. Unit of Infectious Diseases, Internal Medicine, General Hospital of Rosell, Cartagena, Murcia, Spain
8. Unit of Infectious Diseases, Hospital Universitario de San Sebastian, San Sebastian, Spain
9. Unit of Infectious Diseases and Microbiology, University Hospital of Puerto Real, Cádiz, Spain
10. Unit of Infectious Diseases, University Hospital of Valme, Sevilla, Spain (J.A. Pineda)
11.  University Hospital of Jaen, Jaen, Spain
12. Unit of Infectious Diseases, General University Hospital, Murcia, Spain
13. Unit of Infectious Diseases, University Hospital Reina Sofía of Córdoba, Maimonides Institute of Biomedical Research of 
Córdoba, University of Córdoba, Córdoba, Spain
14. Unit of Tropical Medicine, Hospital of Poniente, El Ejido, Almería, Spain
15. Department of Microbiology, Hospital Infanta Elena of Huelva, Huelva, Spain
16. Clinical Management Unit of Digestive Diseases, University Hospital of Virgen del Rocío, Sevilla, Spain
17.  KU Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Clinical and 
Epidemiological Virology, Leuven, Belgium
Correspondence: Féderico García (fegarcia@ugr.es)
Citation style for this article: 
Pérez Ana Belen, Vrancken Bram, Chueca Natalia, Aguilera Antonio, Reina Gabriel, García-del Toro Miguel, Vera Francisco, Von Wichman Miguel Angel, Arenas 
Juan Ignacio, Téllez Francisco, Pineda Juan A, Omar Mohamed, Bernal Enrique, Rivero-Juárez Antonio, Fernández-Fuertes Elisa, de la Iglesia Alberto, Pascasio Juan 
Manuel, Lemey Philippe, Garcia Féderico, Cuypers Lize. Increasing importance of European lineages in seeding the hepatitis C virus subtype 1a epidemic in Spain. 
Euro Surveill. 2019;24(9):pii=1800227. https://doi.org/10.2807/1560-7917.ES.2019.24.9.1800227
Article submitted on 27 Apr 2018 / accepted on 18 Dec 2018 / published on 28 Feb 2019
Background: Reducing the burden of the hepatitis C 
virus (HCV) requires large-scale deployment of inter-
vention programmes, which can be informed by the 
dynamic pattern of HCV spread. In Spain, ongoing 
transmission of HCV is mostly fuelled by people who 
inject drugs (PWID) infected with subtype 1a (HCV1a).
Aim: Our aim was to map how infections spread within 
and between populations, which could help formulate 
more effective intervention programmes to halt the 
HCV1a epidemic in Spain. Methods: Epidemiological 
links between HCV1a viruses from a convenience sam-
ple of 283 patients in Spain, mostly PWID, collected 
between 2014 and 2016, and 1,317, 1,291 and 1,009 
samples collected abroad between 1989 and 2016 
were reconstructed using sequences covering the NS3, 
NS5A and NS5B genes. To efficiently do so, fast maxi-
mum likelihood-based tree estimation was coupled to 
a flexible Bayesian discrete phylogeographic inference 
method. Results: The transmission network structure 
of the Spanish HCV1a epidemic was shaped by contin-
uous seeding of HCV1a into Spain, almost exclusively 
from North America and European countries. The latter 
became increasingly relevant and have dominated in 
recent times. Export from Spain to other countries in 
Europe was also strongly supported, although Spain 
was a net sink for European HCV1a lineages. Spatial 
reconstructions showed that the epidemic in Spain 
is diffuse, without large, dominant within-country 
networks. Conclusion: To boost the effectiveness of 
local intervention efforts, concerted supra-national 
strategies to control HCV1a transmission are needed, 
with a strong focus on the most important drivers of 
ongoing transmission, i.e. PWID and other high-risk 
populations.
Introduction
An estimated 70 million people are currently infected 
with the hepatitis C virus (HCV) and about 400.000 
die each year from HCV-related chronic liver diseases. 
Highly effective antiviral regimens have become availa-
ble but, as up to 80% of infected patients remain undi-
agnosed [1], scaling up treatment alone will not suffice 
to eradicate the virus on a global scale. Prevention of 
new infections remains a primary objective, especially 
because the number of new infections has been rising 
since 2010 [2]. While HCV subtypes often have a shared 
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geographical distribution or comparable prevalence 
rates among risk groups in the same location, this does 
not imply that their distribution is necessarily shaped 
by similar transmission histories [3]. Because specific 
sub-epidemic patterns of spread can undermine the 
success of public health intervention programmes, a 
case-by-case investigation that considers local charac-
teristics is warranted [4,5].
HCV accrues genetic differences on the same time 
scale as epidemiological processes develop, making it 
possible to trace the spread of the virus among individ-
uals from viral genetic information using phylogenetic 
approaches [6]. A phylogenetic tree depicts the ances-
tor–descendant relationships between the viruses 
that infect different individuals through branches that 
connect the observed data (the tips) and the inferred, 
unobserved ancestors (the nodes). Contrary to tra-
ditional epidemiological methods, coalescent-based 
phylogenetic reconstructions need only a small number 
of samples to infer the population dynamics over time. 
However, small datasets do not provide much resolu-
tion on transmission linkage and migration histories, 
which largely depend on the availability of genetic 
information of HCV strains circulating in epidemiologi-
cally relevant populations [7]. Fortunately, increasingly 
detailed sampling of the global and Spanish HCV1a 
epidemic has become available in recent years thanks 
to expanding sequencing efforts in the context of rou-
tine care and drug resistance research [8]. This allows 
Table 1
Composition of hepatitis C virus subtype 1a gene-specific datasets, 1989–2016 (n = 3,998)
Region Country
NS3 NS5A NS5B
n % n % n %
Anglosphere
Australia 37 2.4 19 1.4 40 3.7
India NA NA 16 1.5
New Zealand 49 3.2 NA 49 4.6
Pakistan 1 0.1 1 0.1 1 0.1
Regional total 87 5.6 20 1.5 106 9.9
Europe (excluding Spain)
Belgium 18 1.2 NA 3 0.3
Cyprus NA NA 14 1.3
France 437 28.1 5 0.4 5 0.5
Germany 105 6.8 9 0.7 23 2.1
Italy 129 8.3 68 5.0 41 3.8
Netherlands 1 0.1 1 0.1 81 7.6
Sweden NA 38 2.8 NA
Switzerland 44 2.8 45 3.3 45 4.2
United Kingdom 4 0.3 NA 117 10.9
Regional total 738 47.5 166 12.1 329 30.7
Far East
China 1 0.1 1 0.1 31 2.9
Japan 1 0.1 NA NA
Thailand 17 1.1 17 1.2 NA
Vietnam NA NA 18 1.7
Regional total 19 1.2 18 1.3 49 4.6
Middle East
Iran NA NA 8 0.7
Saudi Arabia NA NA 41 3.8
Regional total NA NA 49 4.6
North America
Canada 2 0.1 3 0.2 3 0.3
United States 370 23.8 1,037 75.5 472 44.1
Regional total 372 23.9 1,040 75.7 475 44.4
South America
Brazil 101 6.5 46 3.4 NA
Uruguay NA 1 0.1 1 0.1
Regional total 101 6.5 47 3.4 1 0.1
Spain Spain 237 15.3 82 6.0 62 5.8
Total 1,554 100 1,373 100 1,071 100
NA: not available.
Sequence data from 24 countries contributed to at least one gene dataset. All data from Spain were newly generated in the context of drug 
resistance testing between 2014 and 2016. Countries were grouped into seven regions to minimise the impact of potential sampling biases. 
Listed are the absolute number of sequences per country (n) and relative proportion (%) with respect to the total number of sequences in the 
dataset. Cells marked NA indicate that no sequence data from this country was available to include for a particular dataset.
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us to bypass the reconstruction of contact networks 
from patient interviews, which are difficult to interpret 
because of the chronic nature of HCV infection.
The estimated prevalence of HCV in Spain is similar to 
other countries in Western Europe and lies between 
0.5% and 1% [9]. HCV1a is responsible for a quarter of 
all HCV infections in Spain [10,11] and reaches up to 
40% among people who inject drugs (PWID), the risk 
group at the core of the current HCV epidemic [10,12]. 
So far, the Spanish national HCV programme has pri-
oritised universal access to treatment [13], ensuring a 
large increase in the uptake of antiviral therapy across 
infected populations. However, it has been estimated 
that around 60–70% of the Spanish HCV-infected 
population remains undiagnosed. Recent data indicate 
that per five patients that are cured, only one patient is 
newly diagnosed, suggesting that Spain will soon reach 
a diagnostic burn-out [1]. The need for extended screen-
ing efforts with a focus on the populations at highest 
risk is now being addressed and is complemented by 
prevention strategies such as needle exchange and 
opioid substitution programmes [13]. The effectiveness 
of local and national intervention efforts, however, 
partly depends on the extent to which transmission 
is driven by local propagation: when an epidemic is 
driven by migration, the success of local intervention 
programmes is co-determined by how well transmis-
sion can be interrupted elsewhere [14].
Here, we capitalise on sequence data of the NS3, NS5A 
and NS5B genes generated in the context of the Group 
for the Study of Viral Hepatitis (GEHEP) national pro-
gramme to evaluate the relevance of virus movements 
for the Spanish HCV1a epidemic.
Methods
Newly generated sequence data for the hepatitis 
C virus from Spain
We generated viral sequences for a convenience sam-
ple of 283 HCV1a infected patients who attended one 
of the 24 specialised clinical centres spread through-
out Spain (Supplementary Figure S1) and participated 
in the GEHEP programme. At the time of sampling, 231 
patients were naive for direct acting antiviral (DAA) 
treatment, while for 52 patients, a viral sequence at 
time of therapy failure was obtained because no sam-
ple was available at baseline. In the context of antivi-
ral drug resistance, genetic sequencing was performed 
at the San Cecilio Hospital in Granada. Dependent on 
the composition of the DAA regimen that was admin-
istered and on the sample’s volume, one, two or three 
genetic regions in the HCV genome (NS3, NS5A and 
NS5B) were targeted using assays developed in house 
(see  Supplement). Overall, 398 amplification and 
sequencing reactions were successful, and the first 
available sample from each patient was used in subse-
quent analyses. Of these, data from all three fragments 
were available for 37 patients, for another 24 patients, 
two genomic regions were successfully sequenced 
and for the remaining 222 patients, one viral genetic 
sequence was obtained. All sequences generated in 
this study have been submitted to GenBank (accession 
numbers: MG738825–MG739222).
Dataset compilation
The newly generated sequence data from Spain were 
complemented with time- and geo-referenced viral 
genetic data available in GenBank ( https://www.ncbi.
nlm.nih.gov/  ) following the methodology detailed by 
Cuypers et al. [4]. Briefly, the procedure started from 
the sequences that were unambiguously subtyped as 
HCV1a. Clonal sequences, strains from non-human 
hosts and duplicate data were excluded and a multiple 
sequence alignment was generated using a codon-cor-
rect alignment tool [15]. Sequences with stop codons 
and those covering less than 80% of the new NS3, 
NS5A or NS5B sequence data were discarded. In a final 
step, we retained only sequences from peer-reviewed 
publications with known sampling time and location.
In addition, to reduce the size of the dataset with-
out losing accuracy when estimating the quantity 
Figure 1
Support for North America as the origin of all currently 
circulating hepatitis C virus subtype 1a strains, 1989–2016 
(n = 3,998)
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Frequency of North America as root state location
The frequency distribution of locations at the root of the 
phylogenetic tree, or how likely the virus is to reside at a particular 
location at the start of the epidemic, is a parameter of the 
phylogeographic model, and the x-axis denotes this frequency 
for North America. The y-axis values or density values correspond 
to the proportion of trees for which a particular frequency was 
observed and can be thought of as the heights of the bars in 
a histogram. The shift of the density profile towards higher 
frequencies shows that the posterior probability of North America 
as the location of origin increases when sharing the geographical 
information across the gene datasets.
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of between-country migration flows, within-country 
migration networks were represented by a randomly 
chosen taxon of that network. The latter were identi-
fied as clades with at least 95% bootstrap support for 
which all taxa shared their sampling location. To this 
end, maximum likelihood trees were inferred from 
1,000 bootstrapped alignments with RAxML v.8.2 
under a GTR + Γ substitution model. All well-supported 
clades consisting exclusively of sequences from the 
same country were reduced to a single randomly 
selected strain from these clades, except for Spanish 
clades. For the NS3, NS5A and NS5B datasets, respec-
tively 391, 163 and 22 sequences were removed. The 
resulting alignments covered 513 nt of NS3, 258 nt of 
NS5A and 312 nt of NS5B and contained 1,554, 1,373 
and 1,071 sequences, respectively. The NS5A and 
NS5B alignments were shorter than the NS3 alignment 
because the amino acids relevant for drug resistance 
in NS5A are located only within domain I of the protein 
and because of the short length of the commonly 
sequenced conserved region within NS5B, targeted to 
determine the correct HCV genotype. A detailed over-
view of the datasets is provided in Table 1.
Phylogenetic and phylogeographic inference
To efficiently reconstruct the history of viral spread 
from large datasets, we created a pipeline in which 
fast maximum likelihood-based tree estimation, root-
ing and branch length rescaling methods were com-
bined with a flexible and scalable Bayesian discrete 
phylogeographic approach. Briefly, uncertainty about 
the reconstructions was taken into account by condi-
tioning the phylogeographic reconstructions on the 
time-calibrated phylogenies estimated from 1,000 
bootstrapped alignments. For more details on the pipe-
line, we refer to the Supplementary material.
Figure 2
Global migration history of hepatitis C virus subtype 1a, estimated from the NS3, NS5A and NS5B gene fragments, ca 1904–
2016 (n = 3,998)
A. NS3 (n = 1,554) B. NS5A (n = 1,373)
C. NS5B (n = 1,071)
1900 1925 1950 1975 2000 2015
1900 1925 1950 1975 2000 2015
1900 1925 1950 1975 2000 2015
Anglosphere
Region
Europe excluding Spain
Far East
Middle East
North America
South America
Spain
The branches in the time-scaled HCV1a maximum clade credibility trees constructed for the three genes are coloured by their most probable 
location state. The trunk lineages, marked in lighter green, reside in North America.
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The timed trees were used to infer the migration pro-
cesses with a model that allows for different migra-
tion rates to and from locations (i.e. the migration rate 
from location A to location B is allowed to be different 
from the migration rate in the opposite direction). The 
relative importance of the sampling locations varies 
across the gene-specific datasets (Table 1), which will 
affect the estimated intensities of virus movements 
between locations [16,17]. Following Faria et al. [18], 
we attempted to mitigate the impact of sampling het-
erogeneity by combining the geographical information 
from the three gene datasets when reconstructing the 
history of virus spread. As it is well established that 
the origin of all currently circulating HCV1a lineages is 
on the North American continent [4,19], we used the 
posterior probability (PP; this can be interpreted as the 
probability that the reconstructed location is true given 
the data and the model) of North America as root state 
location to evaluate whether simultaneously drawing 
information from multiple datasets improved the accu-
racy of the spatiotemporal estimates. The impact of 
sampling heterogeneity was also minimised by group-
ing all taxa at a higher-order level. Our choice of group-
ing reflected the pragmatic need to mitigate the impact 
of the sampling process on the inferred migration links 
without resorting to an overly coarse categorisation. 
The grouping was also informed by the literature and 
was designed to capture relevant higher-level migra-
tion flows. Specifically, we took into account (i) that 
the origins of the current HCV1a diversity lie in North 
America [4,19], (ii) that there are cultural and/or his-
torical links – and therefore indirectly perhaps also 
pathogen migration links [20] – between Spain and 
other countries in Europe as well as between Spain 
and Latin America [21], and (iii) that HCV1a lineages 
are mainly transmitted by PWID [22] and it is therefore 
possible that routes of virus spread might overlap with 
international drug trafficking routes [23]. We chose to 
group the samples in the following categories (Table 1): 
Spain, Europe excluding Spain (all non-Spanish isolates 
from Europe), North America (accounting for the United 
States and Canada), Anglosphere (all English-speaking 
countries except for those in North America and the 
United Kingdom), Far East, Middle East and South 
America.
A model-averaging procedure (the Bayesian stochastic 
search variable selection procedure) was used to iden-
tify the migration pathways that are most relevant in 
the history of spread, while SpreaD3 [24] was used to 
calculate the statistical support (expressed as Bayes 
factors (BF)) for all possible types of virus movements. 
Estimates of the number of migration events between 
all sampled locations were obtained by probabilisti-
cally mapping the evolution of location state changes 
onto the phylogenies [25]. These estimates were post-
processed using scripts developed in house in the Perl 
and R programming languages to derive the propor-
tions of specific types of migration events and their 
dynamics through time.
The size structure of transmission networks in the 
HCV1a epidemic in Spain was evaluated with a phy-
logeographic rarefaction curve. This is a plot of the 
expected number of introduction events into a specific 
location as a function of the number of taxa randomly 
selected from all taxa sampled at that location [3]. The 
plot was created from 250 spatially annotated phy-
logenies. Because each introduction event marks the 
start of a local transmission network, and the prob-
ability of detecting a previously unrecognised intro-
duction event hence depends both on the number of 
Spanish transmission networks in the sample and on 
their relative abundance, the gradient of the slope 
holds epidemiologically relevant information. In one 
extreme, all sampled viruses from Spain originate from 
a single transmission network and the curve will have a 
zero-degree slope as additional isolates represent the 
already detected network. In the other extreme, when 
all isolates represent different transmission networks, 
the curve is expected to have a constant slope.
Table 2
Posterior probabilities for all types of hepatitis C virus subtype 1a migrations between the regional groupings, ca 1904–2016 
(n = 3,998)
To
Anglosphere Europe excluding Spain Far East Middle East North America South America Spain
From
Anglosphere 2.20 0.48 0.04 0.51 0.17 0.08
Europe excluding Spain 2.93 1.16 0.11 3.74 0.44 11.94
Far East 0.12 0.07 0.02 0.10 0.02 0.02
Middle East 0.01 0.03 0 0.01 0.01 0.02
North America 8.69 39.47 4.57 3.18 0.66 11.60
South America 1.26 1.56 0.02 0 1.29 0.15
Spain 0.02 3.11 0.02 0.02 0.11 0.04  
Posterior probabilities (%) for migration rates supported by a Bayes factor ≥ 50 are marked in bold.
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Ethical statement
The Ethics Committee of the San Cecilio Hospital, 
Granada, approved the study. No informed consent 
was required as patient information was anonymised 
and de-identified before analysis.
Results
Three samples of the hepatitis C virus subtype 
1a evolutionary history
The varying geographic composition of the NS3, NS5A 
and NS5B datasets (Table 1) implied that they may cap-
ture varying details of the epidemic spread of HCV1a in 
more detail than the other datasets do. For example, 
the contribution of European and North American data 
to the NS5B dataset was smaller (69.5%) than their 
contribution to the NS3 (86.5%) and NS5A (93.6%) 
datasets, probably a consequence of the intensive 
global use of this gene region for subtyping purposes. 
Therefore, NS5B may provide a more accurate view of 
migration patterns involving non-Western countries. 
In contrast, the NS3 and NS5A datasets contained 
sequence information for countries for which no NS5B 
data were available.
When evaluating the impact of simultaneously drawing 
geographical information from the three gene datasets, 
support for North America as the root state location 
was notably higher, while not overwhelming, when 
compared with the estimates from the individual gene 
datasets (Figure 1). For this reason, we report here only 
results of analyses in which the location information is 
shared across the gene partitions.
North America and Europe as origins of 
hepatitis C virus subtype 1a in Spain
The maximum clade credibility summary trees esti-
mated from the three gene datasets were in line with 
North America being the origin of the current HCV1a 
pandemic. The many North American lineages that 
survived into the 21st century also show that North 
America continued to be an important source location 
throughout the epidemic history (Figure 2). Focusing 
on the locations for which the epidemiological link-
age is well supported (Table 2), we find that North 
America was the dominant origin location of migration 
events (72.9%). Of these events, 12.5% were directed 
towards Spain. Europe was the second largest source, 
and 60.4% of the migrations from within the European 
continent were directed towards Spain. We also found 
good support (BF ≥ 50) for Spain as a source location 
for HCV1a in other European countries, but not for 
North America (Table 2). The imbalance in the number 
of incoming and outgoing virus movements (mean: 202; 
95% highest posterior density (HPD): 142–258) shows 
that Spain acted as a sink for HCV1a in Europe. With 
the exception of a weakly supported link from Spain to 
South America (BF support of 4.7), no other pathways 
that involve Spain were supported by the data.
To investigate temporal trends in the relative impor-
tance of North America and Europe as source locations 
for HCV1a migration to Spain, the frequency of intro-
ductions into Spain separated by origin location was 
plotted over time (Figure 3). This revealed a stable pat-
tern throughout the largest part of the 20th century. 
However, near the end of the century, the frequency 
of introductions from overseas decreased in favour 
of other European countries (Figure 3).  Figure 3  also 
visualises that the HCV1a epidemics in other regions in 
the world were contributed little (1.1%) to the Spanish 
one.
Numerous hepatitis C virus subtype 1a 
introductions fuel the Spanish epidemic
We estimated a phylogeographic rarefaction curve for 
each of the gene segments to evaluate the size struc-
ture of the transmission network in more detail (Figure 
4). For the three datasets, a similar pattern with an 
almost constant slope was observed. Our sample of 
the Spanish HCV1a epidemic thus indicates that there 
were many smaller, similar-sized transmission clus-
ters rather than one or a few larger, dominant trans-
mission networks. The absence of a clear inflection 
point shows that a larger sample will probably identify 
more introduction events. This pattern agreed with 
Figure 3
The importance of origin locations for hepatitis C virus 
subtype 1a varies during the twentieth century, Spain 
(n = 3,998)
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the absence of well-supported Spanish clusters in the 
NS5A dataset, and with a limited number in the NS5B 
(one 2-taxon cluster) and NS3 (five 2-taxon clusters) 
datasets (Supplementary Table S1). 
Discussion
In this study, we have described the changing trans-
mission flows that connect the Spanish HCV1a 
transmission networks with those elsewhere. Our 
results highlight that the Spanish HCV1a epidemic is of 
a diffuse nature because it is not structured as a small 
number of large transmission networks that were par-
ticularly successful in fuelling the spread of HCV1a in 
Spain. Instead, the circulation patterns were shaped 
by many introduction events from abroad, particularly 
from other European countries and North America. 
Figure 4
Phylogeographic rarefaction curves of the hepatitis C virus subtype 1a epidemic for the NS3, NS5A and NS5B gene datasets, 
Spain (n = 3,998)
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Hence, the outcome of Spanish efforts to control HCV1a 
spread is also dependent on reducing the prevalence 
in the groups that are at most risk in other European 
countries and North America. Given that PWID are the 
major source of ongoing HCV transmission in these 
countries [26], this calls for an intensification of close 
follow-up and treatment in this population, as well as 
needle exchange and opioid substitution programmes. 
Of note, the absence of clear phylogenetic structuring 
of other HCV subtypes in European PWID by geographi-
cal region indicates that the pattern that we recovered 
for subtype 1a may be a general one [27].
The link between pathogen dispersal routes and tim-
ing, and the intensity of human migration fluxes is well 
established [20]. Traffic is less intense between South 
America and Europe (including Spain) than between 
North America and Europe (including Spain). That the 
spread of HCV1a in South America [28] is more recent 
than in North America, the cradle of all current HCV1a 
lineages [4,19], probably accounts for the absence of 
substantial import of HCV1a into Spain from South 
America (BF < 50). The changing importance of North 
America and Europe as dominant source locations for 
new HCV1a lineages also links to shifts in the destina-
tion of historic migration waves. At the beginning of the 
20th century, there was a large outflow from Spain to, 
and re-migration from, North America, whereas from 
the 1950s onwards, emigration was predominantly 
directed to European destinations [21,29]. Temporal 
changes in the intensity of other activities that involve 
cross-border interactions with other European coun-
tries such as trade and tourism are also in line with this 
trend [30].
During the second half of the 20th century, there was a 
continuous improvement in medical procedures, paral-
leled by other societal changes that resulted in a shift 
from mostly iatrogenic spread to an epidemic with 
injecting drug use as the main risk factor for HCV1a 
transmission in resource rich settings [26], including 
Spain [12]. Unfortunately, we could not directly assess 
this because data on risk behaviour were not avail-
able. However, most patients (69%) from Spain were 
sampled in 2014 and 2015, when drug resistance test-
ing was predominantly available to infectious disease 
specialists; these patients were therefore mainly HIV/
HCV-co-infected. From late 2015 onwards, requests 
for drug resistance testing shifted towards hepatolo-
gists, which implies that from then on, most tested 
patients were HIV-negative. As injecting drug use is 
by far the predominant risk behaviour (> 75%) for HIV/
HCV-co-infected patients in Spain and 70% of the HIV-
negative HCV1a patients are infected through injecting 
drug use ([12] and data not shown), our dataset most 
likely to a large extent captures the HCV1a dynamics 
among PWID. Knowledge of the age distribution of the 
Spanish patients would allow us to pinpoint more pre-
cisely to what extent drug user networks and re-migra-
tion of former economic migrants [31] are responsible 
for the increased influx of HCV1a from within Europe. 
This type of information is commonly available for evo-
lutionary investigations of the HIV epidemiology [32]. 
The ability of such information to assist in identifying 
sub-populations at increased risk of HCV infection or 
sub-populations that disproportionally contribute to 
HCV spread will undoubtedly stimulate its use in future 
studies [33]. Note that the small number of clusters 
that represent HCV transmission within Spain a pri-
ori prevent a confident assessment of the circulation 
within the country but not between countries, and of 
the infection dynamics within different demographic 
and behavioural subgroups. Hence, the observation 
that in five of six pairs, both samples originated from 
the south of Spain should be interpreted with caution.
Confidence in the inferred evolutionary relationships 
generally increases with increasing sequence lengths. 
It is thus of interest to sequence longer stretches of the 
virus genome. Although the precision of estimates can 
also be boosted by concatenating multiple genomic 
fragments [34], we chose not to do so here because 
for most patients, only data from one gene segment 
was available. Pinpointing the geographic origin of 
imported lineages more precisely is useful when test-
ing epidemiological hypotheses, but we did not pursue 
this here because the contribution of many European 
countries to the gene datasets was limited and vari-
able. In fact, we grouped the sampling locations by 
region specifically to counteract the influence of geo-
graphical imbalances in the datasets. This, and shar-
ing the geographical information across the datasets, 
improved the ancestral reconstructions. Nonetheless, 
the frequency with which North America was inferred 
as root state location (mean: 38%; 95% HPD: 10.3–
66.2) was not high. We believe that the short length of 
the alignments and the consequently high phylogenetic 
uncertainty, combined with stochastic error in the esti-
mation of the locations, adequately explain this level 
of uncertainty, although a bias may remain despite all 
precautions. The structured coalescent represents an 
attractive alternative to this problem, but the computa-
tional demands imposed by the size and complexity of 
datasets such as those used in this study are currently 
still prohibitive [16]. Alternatively, a possible confound-
ing effect of sampling biases can also be prevented by 
incorporating external epidemiological data [35].
In summary, we found that the HCV1a epidemic in Spain 
was heavily mixed with epidemics elsewhere. This 
provides a contemporaneous rationale for concerted 
anti-HCV actions in Spain, Europe and, to a somewhat 
lesser extent, North America.
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